全球心臟生物标记诊断产业（2024-2029）

Global Cardiac Biomarkers Diagnostics Industry, 2024-2029

出版日期: 2025年01月20日 | 出版商:

Frost & Sullivan | 英文 70 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录

心血管疾病盛行率上升和高灵敏度 POCT 推动心臟生物标记诊断的变革性成长

由于心血管疾病 (CVD) 盛行率不断上升、多重生物标记和诊断检测技术的进步、 POCT 的采用率不断提高以及对预防性医疗保健的重视，全球心臟生物标记诊断市场预计将实现强劲增长。心血管疾病是全球主要死亡原因之一，凸显了早期发现和早期疗育的重要性。世界卫生组织（WHO）估计，2030年将有2,330万人死于心血管疾病。其中，急性心肌梗塞（AMI）、急性冠状动脉症候群、心臟衰竭最受研究人员和医学专业人士的关注。急性心肌梗塞是一种常见疾病，占全球死亡人数的三分之一，因此 AMI 成为世卫组织的重点。

罗氏公司的 Elecsys® Troponin T hs 等针对 AMI 的高灵敏度心肌肌钙蛋白检测方法的进展已成为欧洲和亚洲各地急诊室必不可少的工具，有助于加快诊断速度并改善患者预后。亚太地区是一个快速成长的地区，拥有巨大的未开发成长潜力。

实验室测试和 POCT 在心臟生物标记诊断市场中各自发挥不同的重要作用。实验室测试具有很高的灵敏度和准确性，对于详细的风险评估和持续监测至关重要。相较之下，POCT 可在患者附近快速提供结果，有助于在紧急情况下和偏远地区快速做出决策。速度和准确性的平衡确保了两种测试的持续需求。

由于生物标记检测和技术的进步，以及对更高检测准确性和灵敏度的持续追求，市场竞争处于中等水平。六家公司主导市场：罗氏诊断、雅培快速诊断（原为 Alere）、Quidel Corporation、bioMerieux、西门子医疗和丹纳赫公司。实验室分析设备是一个合併的细分市场，因为公司数量有限，而分析仪器则更加分散，因为公司数量众多。该实验室对于检查和复杂分析至关重要，管理多个标记组（例如 BNP、CK-MB、肌红蛋白、肌钙蛋白）以提供心臟健康的全面视图。

这项研究服务概述了全球心臟生物标记诊断产业以及 2024 年至 2029 年全球市场收益的六年预测。报告涵盖四个地区：北美、欧洲、亚太、中东、北非和南亚（MENASA）以及拉丁美洲。心臟生物标记诊断市场的详细研究包括：

经监管机构核准并在中心实验室中广泛使用的实验室标准化测试：该实验室心臟生物标记领域涵盖的生物标誌物包括肌钙蛋白、高敏肌钙蛋白、BNP/NT-proBNP、hs-CRP、CK-MB 生物标誌物以及其他生物标誌物，如神经调节蛋白-1β、ST2、半乳霜凝集素、血脂谱、乳醣素、血脂谱、乳醣类等。
POCT 涵盖全球市场的肌钙蛋白、BNP、CK-MB、D-二聚体、肌红蛋白生物标记。本研究排除了未经上市前核准而内部设计用于特殊用途的实验室开发的测试。

心臟生物标记是响应心臟损伤或压力而释放到血液中的物质。它们用于心臟衰竭、心肌梗塞和急性冠状动脉症候群等疾病的诊断、风险评估和管理。检测地点可能包括独立实验室、医生办公室、紧急护理机构、疗养院、医院和急诊/室。心臟生物标记诊断范围包括供应商分析，包括仪器、消耗品、试剂、试剂套件和检测试剂。

成长指标
成长动力
成长抑制因素
检测心血管疾病的新生物标记
心臟生物标记诊断的趋势
数位健康和诊断整合模型：心臟诊断
预测考虑因素
收益预测
收益预测分析
按测试类型预测收益
收益预测分析
各地区收益预测
区域收益预测分析：北美
各地区收益分析：欧洲
各地区收益分析：亚太地区
按地区分類的收益分析：中东、北非、南亚和拉丁美洲
价格趋势及预测分析
收益占有率
收益占有率分析
竞赛矩阵
全球心臟生物标记诊断产业：值得关注的活动

成长机会分析：实验室测试的成长要素

成长指标：基于实验室的心臟生物标记诊断
基于实验室的心臟生物标记诊断收益预测
基于实验室的心臟生物标记诊断收益预测分析

成长机会分析：POCT 的成长要素

成长指标：POCT 心臟生物标记诊断
POCT 心臟生物标记诊断的收益预测
POCT心臟生物标记诊断收益预测分析

全球心臟生物标记诊断产业的成长机会领域

成长机会1：高灵敏度检测 (HSA)
成长机会2：用于全面诊断的多标记心臟检测组
成长机会3：面向区域和新兴市场的 POCT 设备
成长机会#4：与穿戴式装置和应用程式集成，实现早期检测和即时监控

附录与后续步骤

成长机会的好处和影响
后续步骤Next steps
附件列表
免责声明

简介目录

Product Code: PFRK-55

Rising Prevalence of CVD and High Sensitivity POCT Driving Transformational Growth in Cardiac Biomarkers Diagnostics

The global cardiac biomarkers diagnostics market is forecast to record robust growth with the increased prevalence of cardiovascular disease (CVD), multiplex biomarkers, advancements in diagnostic testing technology, higher POCT adoption rates, and an intensive focus on preventive healthcare. CVDs are a leading cause of mortality globally, highlighting the importance of early detection and intervention. The World Health Organization (WHO) estimates that in 2030, 23.3 million individuals will die from CVDs. Among these, acute myocardial infarction (AMI), acute coronary syndrome, and heart failure capture the greatest interest of researchers and healthcare professionals. Due to the high frequency-one-third of deaths-of this pathology globally, AMI is a key focus for WHO.

Advancements in high-sensitivity cardiac troponin assays for AMI, such as Roche's Elecsys(R) Troponin T hs make them vital in emergency departments throughout Europe and Asia, speeding up diagnosis and enhancing patient outcomes. Asia-Pacific is the fastest-growing region with high, untapped growth potential.

Lab-based and POCT segments serve critical, distinct roles in the cardiac biomarkers diagnostics market. Lab tests provide high sensitivity and precision, which is essential for detailed risk assessment and ongoing observation. In contrast, POCT delivers rapid results at the patient's side, facilitating prompt decision-making in emergencies and remote locations. This balance of speed and accuracy ensures continued demand for both testing methods.

The market is moderately competitive driven by advances in biomarkers assays and technology alongside a continuous push for enhanced accuracy and high sensitivity of assays. Six players dominate the market: Roche Diagnostics, Abbott Rapid Diagnostics (formally Alere), Quidel Corporation, bioMerieux, Siemens Healthineers, and Danaher Corporation. There are limited players in lab analyzers, making this segment consolidated, while the assays space is more fragmented owing to the presence of numerous players. Labs are essential for precise testing and complex analysis, managing multi-marker panels (e.g., BNP, CK-MB, myoglobin, and troponin) to provide a comprehensive view of cardiac health.

This research service provides an overview of the global cardiac biomarkers diagnostics industry and a 6-year global market revenue forecast from 2024 to 2029. The geographical scope covers four regions: North America, Europe, Asia-Pacific, and the Middle East, North Africa, and South Asia (MENASA) and Latin America. The detailed examination of the cardiac biomarkers diagnostics market includes:

Lab-based standardized tests that are approved by regulators and widely used by centralized labs. The biomarkers covered in this lab-based cardiac biomarkers segment include troponins, high-sensitivity troponins, BNP/NT-proBNP, hs-CRP, CK-MB biomarkers, and other biomarkers such as Neuregulin-1beta, ST2, Galectin, lipid profiles, and Copeptin.
POCT covers troponins, BNP, CK-MB, D-dimer, and myoglobin biomarkers for the global market. The study excludes laboratory-developed tests that are internally designed for specialized use without pre-market approvals.

Cardiac biomarkers are substances released into the bloodstream in response to heart damage or stress. They diagnose, assess risk, and manage conditions such as heart failure, myocardial infarction, and acute coronary syndrome. Testing locations discussed in the study include independent laboratories, physicians' offices, urgent care facilities, nursing facilities, hospitals, and emergency departments/rooms. The cardiac biomarkers diagnostics coverage includes vendor analysis encompassing instruments, consumables, reagents, kits, and assays.

Research Scope

Scope of Analysis
Segmentation
History of Cardiac Biomarkers
Cardiac Biomarkers
Mechanism of Cardiac Biomarkers in Heart Failure

Growth Environment: Transformation in the Cardiac Biomarkers Diagnostics Industry

Why Is It Increasingly Difficult to Grow?
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on the Cardiac Biomarkers Diagnostics Industry

Ecosystem in the Global Cardiac Biomarkers Diagnostics Industry

Competitive Environment
Key Competitors by Region

Growth Generator in the Cardiac Biomarkers Diagnostics Industry

Growth Metrics
Growth Drivers
Growth Restraints
Emerging Biomarkers for the Detection of Cardiovascular Diseases
Cardiac Biomarkers Diagnostics Trends
Digital Health and Diagnostics Inter Convergence Model: Cardiac Diagnostics
Forecast Considerations
Revenue Forecast
Revenue Forecast Analysis
Revenue Forecast by Test Type
Revenue Forecast Analysis
Revenue Forecast by Region
Revenue Forecast Analysis by Region: NA
Revenue Forecast Analysis by Region: Europe
Revenue Forecast Analysis by Region: APAC
Revenue Forecast Analysis by Region: MENASA and Latin America
Pricing Trends and Forecast Analysis
Revenue Share
Revenue Share Analysis
Competitor Matrix
Global Cardiac Biomarkers Diagnostics Industry: Notable Activities

Growth Opportunity Analysis: Growth Generator in Lab-based Tests

Growth Metrics: Lab-based Cardiac Biomarkers Diagnostics
Lab-based Cardiac Biomarkers Diagnostics Revenue Forecast
Lab-based Cardiac Biomarkers Diagnostics Revenue Forecast Analysis

Growth Opportunity Analysis: Growth Generator in POCT

Growth Metrics: POCT Cardiac Biomarkers Diagnostics
POCT Cardiac Biomarkers Diagnostics Revenue Forecast
POCT Cardiac Biomarkers Diagnostics Revenue Forecast Analysis

Growth Opportunity Universe in the Global Cardiac Biomarkers Diagnostics Industry

Growth Opportunity 1: High Sensitivity Assays (HSAs)
Growth Opportunity 2: Multi-marker Cardiac Panels for Comprehensive Diagnostics
Growth Opportunity 3: POCT Devices for Rural and Emerging Markets
Growth Opportunity 4: Convergence with Wearables and Apps for Early Detection and Real-time Monitoring